Egg ovotransferrin-derived ACE inhibitory peptide IRW increases ACE2 but decreases proinflammatory genes expression in mesenteric artery of spontaneously hypertensive rats

Kaustav Majumder¹,², Guanxiang Liang¹, Yanhong Chen¹, LeLuo Guan¹, Sandra T. Davidge²,³,⁴ and Jianping Wu¹,²

¹ Department of Agricultural, Food and Nutritional Science, Faculty of Agricultural, Life and Environmental Sciences, University of Alberta, Edmonton, AB, Canada
² Cardiovascular Research Centre, University of Alberta, Edmonton, AB, Canada
³ Women and Children’s Health Research Institute, University of Alberta, Edmonton, AB, Canada
⁴ Department of Obstetrics and Gynecology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada

Scope: Egg ovotransferrin-derived angiotensin converting enzyme (ACE) inhibitory peptide IRW was previously shown to reduce blood pressure in spontaneously hypertensive rats through reduced vascular inflammation and increased nitric oxide-mediated vasorelaxation. The main objective of the present study was to investigate the molecular mechanism of this peptide through transcriptome analysis by RNAseq technique.

Methods and results: Total RNA was extracted from kidney and mesenteric arteries; the RNAseq libraries (from untreated and IRW-treated groups) were constructed and subjected to sequence using HiSeq 2000 system (Illumina) system. A total of 12,764 and 13,352 genes were detected in kidney and mesenteric arteries, respectively. The differentially expressed (DE) genes between untreated and IRW-treated groups were identified and the functional analysis through ingenuity pathway analysis revealed a greater role of DE genes identified from mesenteric arteries than that of kidney in modulating various cardiovascular functions. Subsequent qPCR analysis further confirmed that IRW significantly increased the expression of ACE-2, ABCB-1, IRF-8, and CDH-1 while significantly decreased the expression ICAM-1 and VCAM-1 in mesenteric arteries.

Conclusion: Our research showed for the first time that ACE inhibitory peptide IRW could contribute to its antihypertensive activity through increased ACE2 and decreased proinflammatory genes expression.

Keywords: ACE-2 / Bioactive peptides / Hypertension / RNAseq / SHR

Additional supporting information may be found in the online version of this article at the publisher’s web-site

© 2015 The Authors. Molecular Nutrition & Food Research published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.mnf-journal.com

1 Introduction

Hypertension, the persistent increase of systolic/diastolic blood pressure over 140/90 mm Hg, respectively, is a major health concern afflicting approximately 1 billion people worldwide [1]. Hypertension is considered as one of the risk factors for cardiovascular diseases (CVDs) accounting for ~30% of global deaths [2, 3]. Since pharmacological antihypertensive therapies are often associated with adverse side effects [4, 5], a safer therapeutic alternative is highly
A novel ACE inhibitory peptide, IRW, identified from egg white protein ovotransferrin [15], was also shown to have anti-inflammatory effects via modulated expression of several adhesion molecules and inflammatory cytokines in cells [17]. Our further in vivo study in spontaneously hypertensive rats (SHRs), a widely used animal model of essential hypertension, demonstrated pronounced antihypertensive effects of orally administered IRW that were likely mediated through several different pathways such as modulation of renin angiotensin system (RAS) through ACE inhibition, reduced vascular inflammation, increased nitric oxide (NO) mediated vasorelaxation though increased expression of endothelial nitric oxide synthase (eNOS) and NO bioavailability by reducing oxidative/nitrosative stress [18]. Similarly, two well known, milk-derived antihypertensive peptides IPP and VPP were also reported to have anti-inflammatory effects in vascular tissue of apolipoprotein-E knockout mice and adipose tissue of mice fed with high-fat diet [19,20]. Lactoferrin-derived peptide RPYL was reported to inhibit angiotensin II (Ang II) induced vasoconstriction by blocking the binding of Ang II with angiotensin receptor 1 (AT1) in rabbit carotid artery [21]. Therefore the mechanism of actions of ACE inhibitory peptides was far more complicated than the inhibition of ACE; it is likely that many of these bioactive peptides exert health benefits through modulation of various biologically active proteins at the transcriptional and posttranscriptional levels. Therefore it is important to evaluate the functions of the bioactive peptides on the transcriptome level to identify the alteration of gene expression that may be responsible for the biological effect.

The transcriptome is defined as the complete set of RNA produced by the genome at a given moment in a given tissue in a selected organism; it is considered an important link between the phenotype and the information encoded in the genome [25]. A high throughput technique termed RNA-sequencing (RNAseq) is now available for genome-wide profiling of the entire transcriptome [24, 25], which can detect the lowly expressed transcripts through in depth sequencing [26]. RNAseq provides opportunities to explore many different aspects of the entire transcriptome and is also useful to quantify the gene expression levels by digital analysis [24]. Thus this technique can be applied to investigate the detailed molecular mechanisms of food-derived compounds. Therefore, the main objective of the present study was to investigate the molecular mechanism of egg protein ovotransferrin derived ACE inhibitory peptide IRW on SHRs through transcriptome analysis by RNAseq technique.

2 Materials and methods

2.1 Animal experimental procedures and sample collections

Animal experiments were performed in SHR as previously described [18]. Animals were randomly assigned to treatment groups: untreated (control, n = 6), and IRW (15 mg/Kg BW, n = 6) for a period of 18 days, and then were sacrificed, and tissues (kidney, aorta, heart, mesenteric arteries; n = 6) were collected, weighed, and stored in RNA stabilization reagent (RNAlater, Qiagen, Toronto, Ontario) at –80°C for future experiments. All experimental protocols were reviewed and approved by the University of Alberta Animal Welfare Committee (Protocol # 611/09/10/D) in accordance with the guidelines issued by the Canada Council on Animal Care and also adhered to the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health. Mesenteric arteries were dissected from the anterior portion of the abdominal aorta and cleaned of adherent surrounding adipose and connective tissues in sterile ice-cold HEPES-PSS (in mmol/L: NaCl 142, KCl 4.7, MgSO4 1.17, CaCl2 4.7, K2PO4 1.18, HEPES 10, and glucose 5.5; pH 7.4) solution in a petri dish. The mesenteric arteries were put in RNA stabilization reagent after cleaning, whereas kidneys were directly put into RNA stabilization reagent and stored in –80°C.

2.2 RNA isolation

Kidney tissue samples were ground into fine powder in liquid nitrogen using oven baked (for sterilization), prechilled mortar and pestle prior to nucleic acid extraction, whereas mesenteric artery samples were cut into small pieces using RNAlater RNA Stabilization Reagent (Qiagen) by sterile blades. The tissue samples (~80 mg) were first homogenized using a Precellys1 24 homogenizer (Bertin Technologies, Montigny, France) with two cycles of 30 s each at 5500 rpm and 10 s pause in between and the total RNA were then extracted using mirVana™ miRNA Isolation Kit (Ambion, Carlsbad, CA), in a phenol-free manner according to the manufacturer’s instructions. The quality and quantity of the RNA were determined using Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) and Qubit 2.0 Fluorometer (Invitrogen, Carlsbad, CA), respectively. Only the RNA samples with integrity number (RIN) higher than or equal to 7.0 were preceded for RNA-seq library construction.

2.3 RNA-seq library construction and sequencing

Total RNA (20 ng/μL) from each sample was used to construct RNA-seq libraries with a unique index using the TruSeq mRNA Sample Preparation kit (Illumina, San Diego, CA) and the quantification of the library was performed using
Qubit 2.0 Fluorometer (Invitrogen, Carlsbad, CA). The libraries were sent to Génomique Québec (Montréal, Canada) for sequencing on a HiSeq 2000 system (Illumina). Sequencing reads were 100 bp paired-end, and they were demultiplexed according to their index numbers with CASAVA version 1.8 (Illumina). Reads that did not pass the Illumina chastity filter test were removed for further analysis.

2.4 RNA-seq reads mapping and annotation

Rat genome (Rattus norvegicus, Rnor_5.0) was downloaded from ENSEMBL (http://uswest.ensembl.org/) server and RNA-seq reads were aligned to the rat genome by using TopHat 2.0.10 with default parameters [27]. The output mapping files from the TopHat2 alignment, along with the GTF file from ENSEMBL (http://uswest.ensembl.org/) rat gene annotation v75.30, were used in the htseq-count (http://www.huber.embl.de/users/anders/HTSeq/) to determine the total number of reads mapped to each gene. The abundance of mRNAs in each library was obtained by normalizing reads number to counts per million reads (CPM), calculated as (gene reads number/total mapped reads number per library) × 1 000 000. The expressed genes with CPM > 1 in at least 60% of the samples was used for further analysis.

2.5 Identification of differentially expressed genes

Differential expression of genes between untreated (Untrt), and IRW-treated (IRW) groups were then assessed using edgeR bioinformatics tool [28]. Only higher abundance genes (CPM>5 in at least 60% of the samples) were used for the identification of differentially expressed (DE) genes. The significantly DE genes were determined based on Benjamini and Hochberg multiple testing correction test by calculating the false discovery rate < 0.05 and fold change (FC) >1.5 (log,FC > 0.6) [29], which is similar to a previous study by Liang et al. [30].

2.6 Functional analysis of differentially expressed genes

Ingenuity pathway analysis (IPA, Ingenuity Systems, www.ingenuity.com) was used to analyze the correlation between gene expression and key functions of vascular tissues and kidney. A threshold of value of $p < 0.01$ was applied to enrich significant biological functions. The functions of significantly expressed DE genes from both the tissues were analyzed. The functional change according to the FC of DE genes and the direction for a given function (increase or decrease) were determined by using the z-score algorithm provided by the IPA server.

2.7 Quantitative real-time PCR (qRT-PCR) analysis

To verify the DE genes obtained from RNA-seq analysis, qRT-PCR was performed on selected genes: angiotensin converting enzyme 2 (ACE-2), ATP-binding cassette-subfamily B (ABCB-1), interferon regulatory factor 8 (IRF-8), E-Cadherin (CDH-1), intercellular adhesion molecule 1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1). The gene-specific primer pairs were designed using Primer Express software (Applied Biosystems, Foster City, CA) (Table 1). The total RNA was reversely transcribed to synthesize the first strand and second strand of complementary DNA (cDNA) using SuperScript® II Reverse Transcriptase (Invitrogen by Life Technologies, Foster City, CA, USA) using the SYBR green chemistry. Thermal cycling was conditioned at 95°C for 20 s for initial denaturation, and then 40 cycled at 95°C for 3 s followed by annealing/extension for 30 s at specific temperature for each primer pair (Supporting Information Table 1). The expression levels were calculated at the cycle threshold values ($C_T$), where the fluorescent signal was detected above background intensity. The relative gene expression was calculated by using ß-actin as a reference gene. Relative gene expression was calculated based on $\Delta CT$ and $\Delta \Delta CT$ values, where $\Delta CT = \Delta CT\text{ (Target gene)} − \Delta CT\text{ (ß-actin)}$; and $\Delta \Delta CT = \Delta CT\text{ (IRW)} − \Delta CT\text{ (Untrt)}$. The fold changes between the untreated (Untrt) and treated (IRW) groups were obtained using $2^{-\Delta \Delta CT}$.

The qRT-PCR data were analyzed using GraphPad Prism 5 (GraphPad software, San Diego, CA) and subjected to un-paired, two-tailed $t$-test ($n = 5–6/group$) to determine the significant difference, if any, between Untrt and IRW groups. A $p$ value of <0.05 was considered statistically significant.

2.8 Data submission

All the RNA-seq data were deposited in the publicly available NCBI’s Gene Expression Omnibus Database (http://www.ncbi.nlm.nih.gov/geo/). The data are accessible through GEO Series accession number GSE65017.

Web link: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65017.

3 Results

3.1 Overview of RNA-seq dataset

A total of 658 605 105 high quality 100 bp reads were obtained from 23 libraries (12 samples from kidney, six Untrt and six IRW, and 11 samples from mesenteric artery, five Untrt and six IRW) with an average of 28 M ± 6 M reads per sample. About 82% of reads from kidney and ~87% in mesenteric artery were mapped to the rat genome (Rattus norvegicus, Rnor_5.0). In total, 12 764 expressed genes were detected.
Table 1. Effect of IRW treatment on differentially expressed (DE) genes from the mesenteric artery (MA) and their biological functions

| Gene name                                      | Type                     | Effects on cardiovascular function       | Fold change in RNAseq | Fold change in qPCR |
|------------------------------------------------|--------------------------|------------------------------------------|-----------------------|---------------------|
| Angiotensin converting enzyme-2 (ACE-2)        | Enzyme                   | (1) Vasoconstriction                     | +24-fold              | +18-fold            |
|                                                 |                          | (2) Hyperactivity of renin angiotensin   |                       |                     |
|                                                 |                          | system                                   |                       |                     |
| ATP-binding cassette, subfamily B-1 (ABCB-1)   | Transporter              | (1) Vasoconstriction                     | +15-fold              | +158-fold           |
|                                                 |                          | (2) Leukocyte quantity                   |                       |                     |
| Interferon regulatory factor-8 (IRF-8)         | Transcription regulator  | (1) Inhibit hyperplasia                  | +9-fold               | +7-fold             |
| E-cadherin (CDH-1)                             | Transporter              | (1) Inhibit hyperplasia                  | +19-fold              | +45-fold            |
| Intercellular adhesion molecule 1 (ICAM-1)     | Transmembrane receptor   | (1) Inhibit vascular inflammation        | −3-fold               | −8-fold             |
| Vascular cell adhesion molecule -1 (VCAM-1)    | Transmembrane receptor   | (1) Inhibit vascular inflammation        | −3-fold               | −7-fold             |

Fold change after RNAseq analysis was performed by calculating logfc ($\log_{2}\text{fold change} = \log_2(\text{treatment/untreated})$). Upregulation of gene expression is expressed by "+" sign and downregulation by "−" sign. Fold change for RNAseq = $2^{\log_2 \text{fc}}$; fold change for qPCR = $2^{\Delta\Delta CT}$, $\Delta\Delta CT = \Delta CT (\text{treatment}) - \Delta CT (\text{untreated})$.

Figure 1. Comparison of gene number detected in kidney (KD) and mesenteric arteries (MA). Total 12,764 genes and 13,352 genes were detected in KD and MA, respectively; out of the 11,890 genes are common to both the tissues types, 874 genes were exclusive to KD and 1462 genes were exclusive for MA.

(CPM > 1 in at least 60% of the samples) in kidney and 13,352 genes in the mesenteric artery. Among these genes, 11,890 genes were expressed in both kidney and mesenteric artery, while 874 genes were exclusive to kidney and 1462 genes to mesenteric artery (Fig. 1).

3.2 Significantly altered gene expression profiles in response to IRW

Analysis revealed that only 17 genes were DE in kidney, two of them were downregulated and the rest were upregulated after IRW treatment. In comparison, 151 genes were DE in mesenteric artery, out of those 37 genes were downregulated and 114 genes were upregulated. All the DE genes identified in both tissues are listed in the Supporting Information Table 2. DE genes were obviously more pronounced in mesenteric artery than that of kidney in terms of fold change after IRW treatment (Fig. 2).

3.3 Functions of DE genes in response to IRW

Functional analysis conducted through IPA server revealed that DE genes after IRW treatment could modulate various physiological functions. As the focus of the current study was to evaluate the effect of IRW treatment on hypertension, further analysis was performed to delineate the functions of the DE genes that can modulate various cardiovascular functions. The DE genes found in the kidney have a modest effect in cellular functions and not altered any pathways related to the cardiovascular system whereas DE genes from the mesenteric artery have significantly affect the functions such as cellular movement, cell-to-cell signaling/interaction, molecular transport, cellular morphology, and cellular maintenance. These altered cellular and molecular functions in mesenteric artery can modulate various diseases and disorders such as inflammatory disease, cardiovascular disease, and immunological function (a higher $-\log_{10}P$ value indicates the greater relevance of the DE genes to that particular function, Fig. 3A). The result indicates that IRW treatment can modulate the expression of genes that are highly related to the cardiovascular function. Further analysis showed that the DE genes from mesenteric arteries could modulate various cardiovascular disease functions such as occlusion of artery, hypertension, and ischemic cardiomyopathy (Fig. 3B). Interestingly, DE genes that can
Figure 2. Effect of IRW on detected differentially expressed (DE) genes in kidney (KD) and mesenteric arteries (MA). Axis X and Y show log2 (fold change) and log2 (normalized reads number) of each DE genes, respectively. DE genes detected in the KD represented by symbol “O” and DE genes detected in MA represented by symbol “+.” The fold changes of the DE genes from KD are much less than gene detected from MA.

Figure 3. Functional role of DE genes from mesenteric arteries (MA). DE genes identified in the MA after IRW treatment can modulate various physiological functions (A): X-axis and Y-axis represent $-\log_{10} P$ value and functions, respectively. A higher $-\log_{10} P$ value indicates a greater relevance to that function. The impact of DE genes identified from MA on cardiovascular disease (B). X-axis and Y-axis represent $-\log_{10} P$ value and cardiovascular disease functions, respectively. Results were obtained from IPA analyses from $n = 5–6$ per treatment for mesenteric arteries.
modulate cardiovascular function also play important roles in controlling inflammation, immunological and metabolic functions. A total of 32 genes were affected in mesenteric arteries that can modulate these various cardiovascular functions, a detailed list of these DE genes and their respective functions in vascular tissues are presented in the Supporting Information Table 3. Given these results, IRW treatment had a greater effect on the mesenteric arteries than that of the kidney; therefore all further experiments were performed only in the mRNA samples isolated from the mesenteric arteries of Untrt and IRW-treated groups.

3.4 Target gene validation

Functional analysis showed that DE genes in the mesenteric artery modulated different cardiovascular functions. Six most interesting DE genes, ACE-2, ABCB-1, IRF-8, CDH-1, ICAM-1, and VCAM-1, were selected for further analysis using qRT-PCR. According to qPCR analysis, expression of four target genes, ACE-2, ABCB-1, IRF-8, and CDH-1, were significantly upregulated, while expression of two target genes, ICAM-1 and VCAM-1, were significantly downregulated in the mesenteric artery of IRW group (Table 1). The potential roles of these genes in modulating cardiovascular disease condition and the impact of IRW treatment are presented in Table 1. These six genes have significant roles in all of these pathways and significant fold change (increase or decrease) observed in the mesenteric artery tissues, qPCR results are in alignment with the RNAseq data (Table 1).

4 Discussion

The relationship between diet and hypertension has been largely recognized by various epidemiological studies [8, 31, 32]. Recent studies have characterized various food bioactive compounds that may be responsible for the treatment and management of hypertension and associated cardiovascular disorders [32–35]. Most of these compounds are plant secondary metabolites such as polyphenols and flavonoids [36, 37]; food protein derived peptides with blood pressure lowering, cholesterol lowering, anti-thrombotic, and anti-oxidant activities have been proven beneficial against CVDs [38–40]. These bioactive compounds can activate signaling pathways and then regulate the expression of specific genes and consequently their translation into the corresponding proteins [41]. There are several studies performed to identify the gene expression changes after treatment of bioactive peptides, using DNA microarray or quantitative real-time PCR (qRT-PCR) techniques [22, 23]. DNA microarray analysis have suggested that IPP and VPP could significantly increase the expression of eNOS, connexin 40, and cyclooxygenase-1 (COX-1) genes, whereas decreased the expression of nuclear factor kappa B subunit (NF-κB) and peroxisome proliferator activator receptor gamma (PPARγ) genes in SHRs [10]. Using RT-PCR analysis, flavonoids, and phenolic compounds from lingonberry and cranberry have been shown to reduce the expressions of ACE, cyclooxygenase-2 (COX-2), monocyte chemoattrac-
tant protein-1 (MCP-1), and P-selectin genes and exhibit anti-inflammatory and anti-thrombotic effect in SHRs [42]. Another study showed that peanut polyphenols could exert hypolipidemic effects by increasing the expression of fatty acid synthase, sterol receptor element-binding protein-1c, acetyl-CoA carboxylase (ACC1), and PPARγ genes in Wistar rats [43, 44]. In this study, we used the nutragenomics [45] based approach to study the effect of oral administration of a bioactive peptide on gene expression profile of vascular tissues through transcriptome analysis performed by RNAseq, a high throughput analysis that could delineate the link between phenotype and information encoded in the genome, which could be used to understand the molecular mechanism of an active food compound. Our study showed that egg protein derived bioactive peptide IRW altered the gene expression in the vascular tissues in adult male SHRs; and 11,890 genes are similar in both kidney and mesenteric arteries but they differentially expressed more in mesenteric arteries than kidney. Functional analysis revealed that DE genes identified from mesenteric arteries have known modulatory roles in various cellular functions, whereas DE genes in kidney have no significant impact at functional level, suggesting a pronounced effect of IRW treatment on mesenteric arteries.

Most reported antihypertensive peptides target at the RAS at the level of ACE inhibition or Ang II receptor blockade. For example, a study by Yu et al. reported that administration of ACE inhibitory peptide, RVPSP, for 4 weeks significantly reduced the mRNA expressions of renin, ACE, and AT1 receptor in kidney [23]. However, specific modulatory effects of bioactive peptides on ACE-2 remain largely unknown. Our study showed that IRW treatment significantly increased the gene expression of ACE-2 without affecting RAS components. Unlike ACE, ACE-2 functions as a carboxy-peptidase, cleaving a single residue from the vasoconstrictor Ang II to generate a vasodilatory peptide angiotensin 1–7 (Ang 1–7). A G-protein-coupled receptor-Mas acts as the Ang1–7 receptor and initiates a counter-regulatory role by opposing Ang-II induced vasoconstriction. Thus ACE-2 contributes to an alternate arm of the RAS pathway, which counterbalances the effects of the classic RAS pathway through degradation of Ang II [46, 47]. The reduction of plasma angiotensin-II level after IRW treatment observed in our previous study [18] could be mediated, at least partially, through increased expression of ACE-2, as revealed in the present study. A recent study by Ehlers et al. concluded that the milk-derived ACE inhibitory peptide IPP might exert additional antihypertensive effects through activation of the ACE-2-Ang1–7-Mas axis of RAS system, although expression of ACE-2 was not determined [7]. ACE-2 is a newly identified arm of RAS pathway; upon activation it can play a vasodilatory role to reduce high blood pressure [46, 47]. Therefore increasing the expression of ACE-2 could mediate the antihypertensive effect through the degradation of vasoconstrictory compound Ang II. Thus, our study documented for the
first time that a food protein-derived ACE inhibitory peptide IRW could contribute to its antihypertensive effect through a new mechanism: increased gene expression of ACE-2.

Our present study also revealed that IRW reduced gene expression of ICAM-1 and VCAM-1 in the mesenteric arteries. The reduced gene expression indicates the suppression of protein upregulation at the transcriptional level, which correlates with the reduced ICAM-1 and VCAM-1, observed in our previous in vivo study [18]. Cellular activation of the proinflammatory transcription factor NF-κB causes nuclear translocation of p65-p50 dimers and thus enhances expression of genes whose protein products (such as ICAM-1 and VCAM-1) mediate leukocyte recruitment under inflammation and consequently contribute toward vascular inflammation and atherosclerosis [48, 49]. We also demonstrated that IRW treatment could inhibit the translocation of both p65 and p50 in endothelial cells [17], which is in agreement with the present study showing downregulation of ICAM-1 and VCAM-1 gene expression in the IRW group.

Another two DE genes are the transporters, CDH-1 and ABCB-1. Expression of these two genes was significantly increased after IRW treatment. As a member of ABC (ATP-binding cassette) proteins, ABCB-1's primary role is to provide a first line of defense at the cellular level by inhibiting entry of potentially harmful compounds into the cell and excreting toxic metabolites out of the cell [50]. Overexpression of ABCB-1 also controls the production of leukocyte and thus can control the inflammatory response [51]. It was also reported that overexpression of ABCB-1 might affect the lipid homeostasis and could increase the reverse transport of cholesterol [52]. Therefore upregulation of ABCB-1 could modulate vascular inflammation via differential regulation of leukocytes and could be helpful in destabilization of atherosclerotic plaque through reverse transport of cholesterol [53]. Some studies suggest that polymorphisms in this transporter gene might affect individual's susceptibility to ischemic heart disease and atherosclerosis, but the results are still inconclusive [54–56]. Moreover, apart from CVDs, increased expression of ABCB-1 gene can also reduce the risk of colitis and inflammatory bowel disease [57], suggesting a potential role of IRW in treating several other disease conditions in addition to CVDs. Another transporter gene, CDH-1 expression was also significantly upregulated by IRW treatment. CDH-1 is a protein belongs to cadherin family whose main function is to help neighboring cells stick to one another (cell adhesion) to form organized tissues [58]. Upregulation of CDH-1 could inhibit the hyperplasia of endothelial and vascular smooth muscle cells [59, 60]. Similarly, another target gene IRF-8 was significantly upregulated by IRW treatment. These results suggest that IRW treatment can reduce vascular inflammation as well as the hyperplasia of the vascular smooth muscle cells, both of which predispose to arteriosclerosis, a complication of long standing hypertension [62, 63].
Increased inflammation and oxidative stress can also lead to fibrosis and remodeling in vascular tissues. Our previous study demonstrated that IRW treatment significantly attenuated type I collagen levels [18], suggesting a reduction in hypertension induced tissue remodeling. Results from the current study are in alignment with our previous findings as the upregulation of CDH-1 and IRF-8 genes inhibits hyperplasia, which may leads to the alteration of tissue fibrosis and vascular remodeling. Additionally, feeding IRW for a period of 18 days did not affect body and organ weights (data not shown), suggesting it is likely safe; further phase-I clinical trial should be performed to validate its safety. Schematic representations of IRW treatment on gene expressions are illustrated in Fig. 4.

In conclusion, IRW increased expression of genes for anti-hypertensive and anti-inflammatory mediators in vasculature concomitant to a downregulation in proinflammatory genes in SHRs. These results may explain the mechanisms underlying the anti-hypertensive, anti-inflammatory, and improved endothelial functions observed upon IRW treatment in vivo. We believe that this is the first study to observe a food-derived bioactive peptide upregulate expression of ACE-2 gene, a vasodilator and anti-inflammatory molecule that may open up novel therapeutic opportunities for the management of vascular and associated inflammatory diseases. Given the oral route of administration, IRW may indeed be well suited for translation as a nutraceutical targeting a number of cardiovascular pathologies. As both RAS and inflammatory pathways affect diverse tissues and organs, a systematic approach to determine IRW’s effects on various physiological and pathological processes is necessary. Indeed our transcriptomics study provides novel evidence supporting the role of IRW in modulating the mechanisms underlying conditions such as inflammatory, metabolic and cardiovascular diseases.

Conceived and designed the experiments: K.M., L.G., and J.W. Performed the experiments: K.M. Analyzed the data: K.M., G.L., and Y.C. Contributed reagents/materials/analysis tools: S.D., L.G., and J.W. Wrote the manuscript: K.M.

This work was supported by research grants from Natural Sciences and Engineering Research Council (NSERC) of Canada and the Alberta Livestock and Meat Agency (ALMA) to J.W. S.D. is a Canada Research Chair in Maternal and Fetal Cardiovascular Health.

The authors have declared no conflict of interest.

5 References

[1] WHO (World Health Organization). A Global Brief on Hypertension, silent killer, global public health crisis- 2013. Available from: URL: http://apps.who.int/iris/bitstream/10665/ 79059/1/WHO_DCO_WHD_2013.2eng.pdf?ua=1.

[2] Hall, J. E., Granger, J. P., do Carmo, J. M., da Silva, A. A. et al., Hypertension: physiology and pathophysiology. Compr. Physiol. 2012, 2, 2393–2442.

[3] Chockalingam, A., World hypertension day and global awareness. Can. J. Cardiol. 2008, 24, 441–444.

[4] Gavras, H., Gavras, I., Angiotensin converting enzyme inhibitors. Properties and side effects. Hypertension 1988, 11, 1137–1141.

[5] Viera, A. J., Neutze, D. M., Diagnosis of secondary hypertension: an age-based approach. Am. Fam. Physician 2010, 82, 1471–1478.

[6] Cicero, A. F. G., Gerocarni, B., Laghi, L., Borghi, C., Blood pressure lowering effect of lactotriptides assumed as functional foods: a meta-analysis of current available clinical trials. J. Hum. Hypertens. 2011, 25, 425–436.

[7] Ehlers, P. I., Nurmi, L., Turpeinen, A. M., Korpela, R., Vapaatalo, H., Casein-derived tripeptide Ile-Pro-Pro improves angiotensin-(1-7)- and bradykinin-induced rat mesenteric artery relaxation. Life Sci. 2011, 88, 206–211.

[8] Turpeinen, A. M., Jarvenpaa, S., Kautiainen, H., Korpela, R., Vapaatalo, H., Antihypertensive effects of bioactive tripeptides—a random effects meta-analysis. Ann. Med. 2013, 45, 51–56.

[9] Boelsma, E., Kloek, J., IPP-rich milk protein hydrolysate lowers blood pressure in subjects with stage 1 hypertension, a randomized controlled trial. Nutr. J. 2010, 9, 52–58.

[10] Yamaguchi, N., Kawaguchi, K., Yamamoto, N., Study of the mechanism of antihypertensive peptides VPP and IPP in spontaneously hypertensive rats by DNA microarray analysis. Eur. J. Pharmacol. 2009, 620, 71–77.

[11] Geleijnse, J. M., Engberink, M. F., Lactopeptides and human blood pressure. Curr. Opin. Lipidol. 2010, 21, 58–63.

[12] Agyei, D., Danquah, M. K., Rethinking food-derived bioactive peptides for antimicrobial and immunomodulatory activities. Trends Food Sci. Technol. 2012, 23, 62–69.

[13] Wu, J., Majumder, K., Gibbons, K., Bioactive Proteins and Peptides from Egg Proteins, Wiley-Blackwell, Singapore 2010, pp. 247–263.

[14] Miguel, M., Aleixandre, A., Anti-hypertensive peptides derived from egg proteins. J. Nutr. 2006, 136, 1457–1460.

[15] Majumder, K., Wu, J., A new approach for identification of novel antihypertensive peptides from egg proteins by QSAR and bioinformatics. Food Res. Int. 2010, 43, 1371–1378.

[16] Huang, W., Shen, S., Nimalarathne, C., Li, S. et al., Effects of addition of egg ovotransferrin-derived peptides on the oxygen radical absorbance capacity of different teas. Food Chem. 2012, 135, 1600–1607.

[17] Majumder, K., Chakrabarti, S., Davidge, S. T., Wu, J. Structure and activity study of egg protein ovotransferrin derived peptides (IRW and IQW) on endothelial inflammatory response and oxidative stress. J. Agric. Food Chem. 2013, 61, 2120–2129.

[18] Majumder, K., Chakrabarti, S., Morton, J. S., Panahi, S. et al., Egg-derived tri-peptide IRW exerts antihypertensive effects in spontaneously hypertensive rats. PLoS One 2013, 8, e82829.

[19] Nakamura, T., Hirota, T., Mizushima, K., Okhi, K. et al., Milk-derived peptides, Val-Pro-Pro and Ile-Pro-Pro, attenuate atherosclerosis development in apolipoprotein e-deficient mice: a preliminary study. J. Med. Food 2013, 16, 396–403.
[20] Aihara, K., Osaka, M., Yoshida, M., Oral administration of the milk casein-derived tripeptide Val-Pro-Pro attenuates high-fat diet-induced adipose tissue inflammation in mice. Br. J. Nutr. 2014, 112, 513–519.

[21] Fernandez-Musoles, R., Castello-Ruiz, M., Arce, C., Manzanares, P. et al., Antihypertensive mechanism of lactoferrin-derived peptides: angiotensin receptor blocking effect. J. Agric. Food Chem. 2014, 62, 173–181.

[22] Yamaguchi, N., Kawaguchi, K., Yamamoto, N., Study of the mechanism of antihypertensive peptides VPP and IPP in spontaneously hypertensive rats by DNA microarray analysis. Eur. J. Pharmocol. 2009, 620, 71–77.

[23] Yu, Z., Yin, Y., Zhao, W., Chen, F., Liu, J., Antihypertensive effect of angiotensin-converting enzyme inhibitory peptide RVPSL on spontaneously hypertensive rats by regulating gene expression of the renin-angiotensin system. J. Agric. Food Chem. 2014, 62, 912–917.

[24] Valdés, A., Simó, C., Ibañez, C., García-Cañas, V., Chapter 5—Emerging RNA-Seq Applications in Food Science—Comprehensive Analytical Chemistry, Elsevier, Oxford 2014, pp. 107–128.

[25] Wang, Z., Gerstein, M., Snyder, M., RNA-Seq: a revolutionary tool for transcriptomics. Nat. Rev. Genet. 2009, 10, 57–63.

[26] Wang, C., Gong, B., Bushel, P. R., Mieg, J. T. et al., The concordance between RNA-seq and microarray data depends on chemical treatment and transcript abundance. Nat. Biotechn. 2014, 32, 926–932.

[27] Kim, D., Pertea, G., Trapnell, C., Pimentel, H. et al., TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013, 14, R36.

[28] Robinson, M. D., McCarthy, D. J., Smyth, G. K., edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010, 26, 139–140.

[29] Benjamini, Y., Hochberg, Y., Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat. Methodol. 1995, 57, 289–300.

[30] Liang, G., Malmuthuge, N., McFadden, T. B., Bao, H. et al., Potential regulatory role of microRNAs in the development of bovine gastrointestinal tract during early life. PLoS One 2014, 9, e92592.

[31] Craddock, S. R., Elmer, P. J., Obarzanek, E., Vollmer, W. M., The DASH diet and blood pressure. Curr. Atheroscl. Rep. 2003, 5, 484–491.

[32] Batchu, S. N., Chaudhary, K. R., Wiebe, G. J., Seubert, J. M., in: Watson, R. R., Preedy, V. R. (Eds.), Chapter 28—Bioactive Compounds in Heart Disease—Bioactive Food as Dietary Interventions for Cardiovascular Disease, Academic Press, San Diego 2013, pp. 431–442.

[33] Fernández-Mar, M. I., Mateos, R., García-Parrilla, M. C., Puertas, B., Cantos-Villar, E., Bioactive compounds in wine: resveratrol, hydroxytyrosol and melatonin: a review. Food Chem. 2012, 130, 797–813.

[34] Al-Shalmani, S., Suri, S., Hughes, D. A., Kroon, P. A. et al., Quercetin and its principal metabolites, but not myricetin, oppose lipopolysaccharide-induced hyporesponsiveness of the porcine isolated coronary artery. Br. J. Pharmacol. 2011, 162, 1485–1497.

[35] Sudano, I., Spieker, L. E., Hermann, F., Flammer, A. et al., Protection of endothelial function: targets for nutritional and pharmacological interventions. J. Cardiovasc. Pharmacol. 2006, 47 (Suppl 2), S136–S150.

[36] Schramm, D. D., German, J. B., Potential effects of flavonoids on the etiology of vascular disease. J. Nutr. Biochem. 1998, 9, 560–566.

[37] Huntley, A. L., The health benefits of berry flavonoids for menopausal women: cardiovascular disease, cancer and cognition. Maturitas 2009, 63, 297–301.

[38] Martinez-Maqueda, D., Miralles, B., Recio, I., Hernandez-Ledesma, B., Antihypertensive peptides from food proteins: a review. Food Funct. 2012, 3, 350–361.

[39] Aleixandre, A., Miguel, M., Muguerza, B., Peptides with antihypertensive activity obtained from milk and egg proteins. Nutr. Hosp. 2008, 23, 313–318.

[40] Cheung, I. W. Y., Nakayama, S., Hsu, M. N. K., Samaranayaka, A. G. P., Li-Chan, E. C. Y., Angiotensin-I converting enzyme inhibitory activity of hydrolysates from oat (Avena sativa) proteins by in silico and in vitro analyses. J. Agric. Food Chem. 2009, 57, 9234–9242.

[41] Getek, M., Czech, N., Fizia, K., Bialek-Dratwa, A. et al., Nutrigenomics—bioactive dietary components. Postepy Hig. Med. Dosw. 2013, 67, 255–260.

[42] Kivimäki, A. S., Ehlers, P. I., Siltari, A., Turpeinen, A. M. et al., Lingonberry, cranberry and blackcurrant juices affect mRNA expressions of inflammatory and atherothrombotic markers of SHR in a long-term treatment. J. Funct. Foods 2012, 4, 496–503.

[43] Bansode, R. R., Randolph, P., Hurley, S., Ahmedna, M., Evaluation of hypolipidemic effects of peanut skin-derived polyphenols in rats on Western-diet. Food Chem. 2012, 135, 1659–1666.

[44] Salamon, H., Bruinsers, N., Lakehal, K., Shi, L. et al., Cutting edge: vitamin D regulates lipid metabolism in Mycobacterium tuberculosis infection. J. Immunol. 2014, 193, 30–34.

[45] Sales, N. M., Pelegrini, R. B., Goersch, M. C., Nutrigenomics: definitions and advances of this new science. J. Nutr. Metab. 2014, 2014, 202759.

[46] Castro-Chaves, P., Cerqueira, R., Pintalhao, M., Leite-Moreira, A. F., New pathways of the renin-angiotensin system: the role of ACE2 in cardiovascular pathophysiology and therapy. Expert. Opin. Ther. Targets 2010, 14, 485–496.

[47] Kuba, K., Imai, Y., Ohoto-Nakanishi, T., Penninger, J. M., Trillogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. Pharmacol. Ther. 2010, 128, 119–128.

[48] Giannotti, G., Landmesser, U., Endothelial dysfunction as an early sign of atherosclerosis. Herz 2007, 32, 568–572.

[49] Poher, J. S., Min, W., Bradley, J. R., Mechanisms of endothelial dysfunction, injury, and death. Annu. Rev. Pathol. 2009, 4, 71–95.

[50] Mori, M., Kasa, S., Isozaki, Y., Kamori, T. et al., Improvement of the cellular quality of cryopreserved bovine blastocysts
accompanied by enhancement of the ATP-binding cassette sub-family B member 1 expression. Reprod. Toxicol. 2013, 35, 17–24.

[51] Ieiri, I., Takane, H., Otsubo, K., The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin. Pharmacokinet. 2004, 43, 553–576.

[52] Jeannesson, E., Siest, G., Bastien, B., Albertini, L. et al., Association of ABCB1 gene polymorphisms with plasma lipid and apolipoprotein concentrations in the STANISLAS cohort. Clin. Chim. Acta 2009, 403, 198–202.

[53] Cucuianu, M., Coca, M., Hancu, N., Reverse cholesterol transport and atherosclerosis. A mini review. Rom. J. Intern. Med. 2007, 45, 17–27.

[54] Pennings, M., Meurs, I., Ye, D., Out, R. et al., Regulation of cholesterol homeostasis in macrophages and consequences for atherosclerotic lesion development. FEBS Lett. 2006, 580, 5588–5596.

[55] Wang, Q., Jin, Y. Z., Zhou, S. B., Wang, L. J. et al., ABCB1 C3435T polymorphism and the risk of ischemic heart disease: a meta-analysis. Genet. Test. Mol. Biomarkers 2014, 18, 636–45.

[56] Keskitalo, J. E., Kurkinen, K. J., Neuvonen, M., Backman, J. T. et al., No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. Br. J. Clin. Pharmacol. 2009, 68, 207–213.

[57] Onnie, C. M., Fisher, S. A., Pattni, R., Sanderson, J. et al., Associations of allelic variants of the multidrug resistance gene (ABCB1 or MDR1) and inflammatory bowel disease and their effects on disease behavior: a case-control and meta-analysis study. Inflamm. Bowel Dis. 2006, 12, 263–271.

[58] Berx, G., Staes, K., van Hengel, J., Molemans, F. et al., Cloning and characterization of the human invasion suppressor gene E-cadherin (CDH1). Genomics 1995, 26, 281–289.

[59] Lee, J. M., Dedhar, S., Kalluri, R., Thompson, E. W., The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell Biol. 2006, 172, 973–981.

[60] Armstrong, E. J., Bischoff, J., Heart valve development: endothelial cell signaling and differentiation. Circ. Res. 2004, 95, 459–470.

[61] Zhang, S. M., Gao, L., Zhang, X. F., Zhang, R. et al., Interferon regulatory factor 8 modulates phenotypic switching of smooth muscle cells by regulating the activity of myocardin. Mol. Cell. Biol. 2014, 34, 400–414.

[62] The Editors. Circulation research thematic synopsis: atherosclerosis. Circ. Res. 2012, 111, e123–e162.

[63] Cizek, S. M., Bedri, S., Talusan, P., Silva, N. et al., Risk factors for atherosclerosis and the development of preatherosclerotic intimal hyperplasia. Cardiovasc. Pathol. 2007, 16, 344–350.